Glenmark Pharmaceuticals announced a significant increase in consolidated net profit after tax (PAT) of ₹482.83 crore for the first quarter ending June 30, 2026. This growth resulted from a strong increase in revenue and a low base effect.
According to regulatory filings, in the same quarter last fiscal year, the company reported a consolidated PAT of ₹46.97 crore. It is worth noting that in the quarter a year prior, the company incurred exceptional expenses of ₹323.23 crore.
Consolidated total operating revenue in the first quarter of the current fiscal year reached ₹4018.48 crore, compared to ₹3264.44 crore during the same period last year. Meanwhile, total expenses in the quarter under review increased to ₹3440.86 crore compared to ₹2872.07 crore.
CMD Glen Saldanha stated that the company began the 2027 fiscal year with broad growth in key markets, reflecting successful execution and business sustainability. He emphasized that India continued to outperform the market, North America demonstrated steady growth driven by the launch of respiratory drugs, and Emerging Markets maintained strong momentum, indicating the strength of the company's diversified global business.
Saldanha added that the results confirmed Glenmark's development strategy, which involves strengthening core business areas while simultaneously expanding differentiated, innovation-based platforms.
Revenue Dynamics by Region
Revenue in the Indian market in the first quarter was ₹1432.1 crore, higher than ₹1239.9 crore the previous year, showing a growth of 15.5 percent. Revenue from North America reached ₹1097.4 crore compared to ₹778 crore in the corresponding period last year. Furthermore, revenue from Europe amounted to ₹747.2 crore compared to ₹667.8 crore in the corresponding period of the last fiscal year.
